Eternal Q1 Profit Surges 268% with Mixed Analyst Ratings on Pharma Stocks
Eternal reported a 268% year-on-year increase in consolidated profit to Rs 92 crore for Q1, alongside a 182% rise in revenue. Market analysts, including Goldman Sachs, maintain a buy rating on Eternal, reflecting positive outlooks. Conversely, Citi has recommended a sell rating on Dr Reddy's Laboratories following its Q1 results. Both articles provide investment insights and stock analysis tools from SEBI-registered experts to guide trading decisions.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 33/100.
Outlets measured: economictimes, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 22 Jul, 09:59 am. Other outlets followed.